Molecular Hydrogen / Revive Therap, DiagnaMed - LARVOL DELTA

Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program (GlobeNewswire) - "Revive Therapeutics Ltd...is pleased to announce that it has entered into a non-binding letter of intent (the 'LOI'), dated February 28, 2025, to acquire the full rights to DiagnaMed Holdings Corp.’s...intellectual property (the 'Acquired Assets') pertaining to molecular hydrogen as potential treatments for neurological and mental health disorders (the 'Acquisition')."

M&A • Amyotrophic Lateral Sclerosis

DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis - "DiagnaMed Holdings Corp...announced in a significant advancement for rare disease research, the Company has been granted Orphan Drug Designation (ODD) for molecular hydrogen in the treatment of amyotrophic lateral sclerosis (ALS) by the U.S. Food and Drug Administration (FDA). This designation underscores the potential of molecular hydrogen as a novel therapeutic option for ALS patients and highlights ongoing efforts to address unmet medical needs in rare disease communities...DiagnaMed and Revive have entered into a non-binding letter of intent (LOI), dated February 28, 2025, with Revive to acquire the full rights to DiagnaMed's intellectual property (the 'Acquired Assets') pertaining to molecular hydrogen for ALS (the 'Acquisition'). The final terms of the Acquisition will be agreed to by the parties after the completion of due diligence by Revive. The Acquisition is expected to close on or before March 31, 2025..."

Commercial • Orphan drug • Amyotrophic Lateral Sclerosis